Filing Flows › Aurinia Pharmaceuticals (AUPH) › Q2 2026 › vs Q1 2026
Aurinia Pharmaceuticals (AUPH) Q2 2026 vs Q1 2026 (quarter over quarter)
Aurinia Pharmaceuticals's revenue rose $5.5M (+7%) from $77.7M in Q1 2026 to $83.2M in Q2 2026. The biggest changes: Net product sales +$5.8M (+8%); License, collaboration and royalty revenue −$334K (-8%). Operating margin 55.7% against 53.3% (+2.4 pts).
Aurinia Pharmaceuticals, Q2 2026: revenue $83.2M (+19% year over year), operating margin 55.7%, net earnings $37.4M, operating cash flow $52.6M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 55.7% | 53.3% | +2.4 pts |
| Net margin | 45.0% | 44.2% | +0.7 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Net product sales | $79.4M | $73.6M | $5.8M | +8% |
| License, collaboration and royalty revenue | $3.8M | $4.1M | −$334K | -8% |
| Revenue | $83.2M | $77.7M | $5.5M | +7% |
| Other income, net | $2.4M | $2.5M | −$58K | -2% |
| Operating profit | $46.3M | $41.4M | $4.9M | +12% |
| Costs & expenses | $36.9M | $36.3M | $596K | +2% |
| Pre-tax earnings | $48.8M | $43.9M | $4.9M | +11% |
| Net earnings | $37.4M | $34.4M | $3.1M | +9% |
| Income tax | $11.4M | $9.6M | $1.8M | +19% |
| Depreciation & amortization | $4.8M | $4.8M | $18K | +0.4% |
| Share-based compensation | $2.8M | $0 | $2.8M | — |
| Working capital & other | $7.5M | −$6.6M | $14.1M | — |
| Operating cash flow | $52.6M | $32.6M | $20.0M | +61% |
Questions
How much did Aurinia Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
Aurinia Pharmaceuticals's revenue rose $5.5M (+7%) from $77.7M in Q1 2026 to $83.2M in Q2 2026.
What drove Aurinia Pharmaceuticals's revenue change in Q2 2026?
Net product sales +$5.8M (+8%); License, collaboration and royalty revenue −$334K (-8%).